Background: There are numerous published studies on the association between RET polymorphisms and susceptibility to Hirschsprung disease (HSCR). However, some of the results are inconsistent and the studies were conducted with small sample sizes. Therefore, we performed a meta-analysis to clarify the relationship.Methods: Relevant data were retrieved from PubMed, Web of Science, Cochrane Library, EMBASE, CNKI, and Google Scholar according to PRISMA guidelines. Odds ratios (OR) were calculated to assess susceptibility to HSCR. Meanwhile, heterogeneity and publication bias were also calculated by R software package (version 4.2.1). The protocol was published in PROSPERO (CRD42022348940).Results: A total of 12 studies were included in the meta-analysis and comprised 12 studies on the RET polymorphism rs2435357 (1,939 subjects and 3,613 controls) and 7 studies on the RET polymorphism rs2506030 (1,849 patients with HSCR and 3,054 controls). The analysis revealed that rs2435357 [A vs. G: odds ratio (OR) = 3.842, 95% confidence interval (CI) 2.829–5.220; AA vs. GG: OR = 2.597, 95% CI 1.499–4.501; AA + AG vs. GG: OR = 6.789, 95% CI 3.0711–14.9973; AA vs. AG + GG: OR = 8.156, 95%CI 5.429–12.253] and rs2506030 (A vs. G: OR = 0.519, 95% CI 0.469–0.573; AA vs. GG: OR = 0.543, 95% CI 0.474–0.623; AA + AG vs. GG: OR = 0.410, 95% CI 0.360–0.468; AA vs. AG + GG: OR = 0.361, 95%CI 0.292–0.447) were significantly associated with susceptibility to HSCR.Conclusions: The polymorphisms rs2435357 and rs2506030 in the RET may be related to susceptibility to HSCR, of which rs2435357 (T > C) is the causal locus and rs2506030 (A > G) is the protective locus. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier:CRD42022348940.
Background: Stage IIB conventional osteosarcoma exhibits highly heterogeneous responses to neoadjuvant chemotherapy, necessitating reliable, noninvasive pre-treatment evaluation systems. Methods: This retrospective study of 198 patients utilized pre-treatment T2-weighted magnetic resonance imaging (MRI) and baseline clinical data. Twelve classical convolutional neural network architectures were benchmarked to identify the optimal imaging backbone. This selected radiomics score was then integrated with core clinical variables using logistic regression to construct a multimodal model. Gradient-weighted Class Activation Mapping++ (Grad-CAM++) and SHapley Additive exPlanations (SHAP) algorithms provided image- and feature-level interpretability. Results: DenseNet121 achieved the highest mean cross-validated area under the curve (AUC; 0.775) and was selected, with AUCs of 0.797 (95% CI: 0.716–0.877) and 0.701 (95% CI: 0.513–0.877) in the training and test cohorts. Adding the clinical variables improved discrimination, yielding a test-cohort AUC of 0.827 (95% CI: 0.661–0.992) with significant reclassification gain over the radiomics-only model (NRI = 1.28, IDI = 0.177; DeLong p = 0.011). Grad-CAM++ activation concentrated on the solid medullary and extraosseous soft-tissue components, and SHAP ranked the radiomics score as the strongest contributor. Conclusions: Integrating deep learning radiomics with key clinical features provides a noninvasive tool for the individualized prediction of neoadjuvant chemosensitivity in osteosarcoma.
Introduction: Pulmonary metastasis in high‐grade conventional osteosarcoma remains a leading cause of treatment failure and mortality. Traditional monitoring methods are insufficient for early detection. This study aims to develop and validate an interpretable machine learning (ML) model using multi‐dimensional data from electronic medical records (EMR) to predict the early risk of pulmonary metastasis in high‐grade conventional osteosarcoma patients. Methods: This retrospective study included data from 522 high‐grade conventional osteosarcoma patients. After rigorous feature selection, 12 independent predictive factors were identified: prothrombin time (PT), international normalized ratio (INR), fibrinogen, globulin, prognostic nutritional index (PNI), eosinophil percentage, monocyte percentage, neutrophil percentage, monocyte count, maximum tumor diameter, gender, and amputation status. Eleven ML models were constructed and compared, with Shapley Additive Explanations (SHAP) analysis applied to enhance model interpretability and clinical transparency. Results: The gradient boosting model exhibited superior performance, achieving an area under the curve (AUC) of 0.891 in the training set and 0.742 in the independent test set. SHAP analysis revealed that tumor maximum diameter was the most influential predictor of pulmonary metastasis risk, while inflammation and coagulation‐related indicators also demonstrated significant contributions. Discussion: The gradient boosting model effectively predicts the early risk of pulmonary metastasis in high‐grade conventional osteosarcoma and provides interpretable risk factors. This model shows potential as a clinical decision support tool, facilitating personalized risk management and precision medicine, aiming to improve patient outcomes.
Background: Parosteal osteosarcoma (PAOS) is a rare and low‐grade primary bone malignant tumor that typically occurs in the distal femur. Traditional reconstruction options for distal femur PAOS include distal femoral replacement (DFR), autografts, and allografts, but issues such as functional sacrifice, insufficient mechanical strength, and low bone union rate limit their further clinical application. 3D‐printed prosthesis, due to the matching shape of various bone defects, could be a novel strategy to reconstruct the hemicortical defect after distal femur PAOS tumor resection. In this study, we designed a 3D‐printed strut‐type prosthesis (3DPSP) to repair the hemicortical defect and evaluated the mid‐term effect in distal femur PAOS. Methods: A retrospective analysis was conducted on patients diagnosed with PAOS at the distal femur between April 2018 and January 2021. Six patients received DFR and six patients received customized 3DPSP reconstruction. Clinical outcomes including oncology status, defect lengths, and ranges of motion of the knee, Musculoskeletal Tumor Society (MSTS) scores, and complications were recorded. X‐ray was performed to evaluate the position and stability of the prosthesis and T‐SMART was applied to assess the interface osteointegration between prosthesis and bone. Results: A total of 12 patients were enrolled in this study with an average follow‐up of 42.1 ± 11.8 months, ranging from 22 to 59 months. In the 3DPSP group, the average operation time was 2.3 ± 0.4 h; the intraoperative blood loss was 175.0 ± 82.2 mL. The average range of motion of the knee was 0°–123° and the mean MSTS score was 28.3 ± 1.6. Compared to the DFR group, the 3DPSP group exhibited significantly less intraoperative blood loss and superior functional recovery. Conclusions: In this study, we designed a novel 3DPSP to reconstruct the hemicortical defect after distal femur PAOS resection. The mid‐term follow‐up result demonstrated that this prosthesis could be an effective reconstruction option for distal femur PAOS patients because of the restored limb function and favorable bone‐prosthesis integration. Further observation of this novel prosthesis is needed.
Background: Although the tumor coagulome interacts with the tumor immune microenvironment (TME) in solid tumors, its role in osteosarcoma (OS) remains uncharacterized. This study aimed to delineate this transcriptomic interplay and identify potential prognostic targets. Methods: This study was performed with bulk RNA sequencing (RNA-seq), single-cell RNA sequencing (scRNA-seq), and clinical phenotype data. Bioinformatic approaches were employed at the transcriptomic level to investigate the impact of the tumor coagulome on the TME and prognosis in OS. We validated the above findings using immunohistochemistry and immunofluorescence. Results: The activity of a coagulation-related transcriptional signature was found to correlate with the degree of malignancy in OS. Its activity score demonstrated predictive value for OS prognosis, with a maximum area under the curve (AUC) of 0.802. scRNA-seq analysis indicated that inflammatory cancer-associated fibroblasts (iCAFs) and APOE+ macrophages were predominantly enriched in the high coagulation score subgroup. Our data further suggest that iCAFs may facilitate the M2 polarization of APOE+ macrophages via the C3–C3AR1 axis, potentially contributing to poorer clinical outcomes in patients with OS. Conclusions: These findings imply that within a high coagulation-related transcriptional score group, the interaction between iCAFs and APOE+ macrophages, likely mediated by the C3–C3AR1 axis, could facilitate OS progression. Consequently, the C3–C3AR1 signaling pathway might represent a promising target for future therapeutic strategies and coagulome monitoring in OS.